Projects

Project Description

Nephrotic Syndrome remains the most common glomerular disease among children with 80% of these children show response to steroid therapy (1). A proportion of children may require steroid sparing agent, one of which is rituximab, which is mostly limited to difficult to treat nephrotic syndrome (not responding to > 2 alternative immunosuppression). Rituximab is a chimeric anti CD-20 antibody, known to suppress B-cell production and remains the choice of alternative immunosuppression in the treatment of frequently relapsing nephrotic syndrome (FRNS), difficult to treat steroid dependent nephrotic syndrome (SDNS) and in steroid resistant nephrotic syndrome (SRNS) who are not responding to standard steroid sparing agents (2).